Prostate cancer test shows greater sensitivity:
This article was originally published in Clinica
Horus Global HealthNet and Speciality Laboratories are to jointly market Horus' ProstAsure computer-assisted test for prostate cancer. The system combines weighted factors for prostate specific antigen (PSA), prostatic acid phosphatase, total creatine kinase and the patient's age. Horus claims this gives a more sensitive and stable indicator of the disease than PSA alone (see Clinica No 705 p 16). Trials showed that the device had a 75% sensitivity and specificity in detecting prostate cancer in men with a normal PSA of less than 4.0ng/ml.
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
In second letter this year targeting email communications, OPDP says that putting the methotrexate oral solution’s risk information below the signature block does not offer ‘prominence and readability’ comparable to the information on the drug’s effectiveness for the treatment of acute lymphoblastic leukemia that was in the body of the email.